bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth

Core Insights - bioAffinity Technologies Inc reported strong growth in its CyPath Lung diagnostic, with a significant increase in revenue despite an overall decline in total revenue due to a strategic shift away from lower-margin lab services [1] Group 1: Financial Performance - CyPath Lung revenue surged by 87% year over year in 2025, with the number of tests performed increasing by 99% [2] - The net loss widened to $14.9 million from $9.0 million a year earlier, influenced by changes in the fair value of warrants, expanded sales activity, and increased clinical development spending [3] - Cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million, following approximately $16.9 million raised in 2025 financings [3] Group 2: Future Outlook - The company anticipates that CyPath Lung unit sales will increase by more than 100% in 2026 as it expands commercialization and clinical validation efforts [4] Group 3: Stock Performance - bioAffinity Technologies shares experienced a significant increase of 124.30%, reaching $2.40, nearing its 52-week low of $0.69 [6] - The Relative Strength Index (RSI) for bioAffinity Technologies surged above 70, indicating strong momentum and suggesting the stock may be entering overbought conditions [5]